Drogek

Orrialde bat drogarako. Eragin tamainak, saiakuntza diseinuak eta neurtu ziren populazioak.

Peptide

Semaglutide

STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.

Dual agonist

Tirzepatide

SURMOUNT-1 and -2, sleep apnoea and heart failure, and about 21% mean weight loss.

Oral

Oral GLP-1

Oral semaglutide and orforglipron — the same mechanism without the injection.

Lotutako irakurketa

Fasting Evidence

Intermittent fasting, time-restricted eating and meal timing, judged on the trial data.

Metabolism Review

Energy expenditure, insulin resistance and metabolic adaptation, without the folklore.

Weight Loss Evidence

Diets, drugs, behaviour and maintenance — ranked by the strength of the evidence behind them.

Sleep Evidence

Sleep, circadian rhythm and the wearables that claim to measure both.

Orri hau automatikoki itzuli da ingelesez. Aipamenak eta zenbakiak aldatu gabe daude. Irakurri ingelesezko jatorrizkoa ezer arraro irakurtzen bada. Irakurri ingelesezko jatorrizkoa